Nucleai closes $33M series B financing

By The Science Advisory Board staff writers

March 24, 2022 -- Artificial intelligence-powered spatial biology company Nucleai closed a $33 million series B financing round, which it will use to advance its spatial biology platform for drug research, development, and diagnostics.

The company said it plans to use the new funding to further develop its platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations, which are applying Nucleai's technology throughout translational research, clinical trials, and novel applications for drug discovery.

The funding round was jointly led by Section 32 and Sanofi Ventures. Existing investors, including Debiopharm, Fosun RZ Capital, Vertex Ventures, and Grove Ventures, participated in this round, the company reported.

Nucleai and Debiopharm team up for cancer drug development
Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter